Skip to content
Deals

Huperzine A and global cognition: grade C

Limited evidence. Direction: Benefit.

C LimitedShort-term only

Educational guidance, not medical advice

Why this grade

Rubric condition met: Clinical-population evidence only, extrapolated to healthy adults

Meta-analyses of trials in people with Alzheimer's disease, mostly at high or unclear risk of bias, found higher MMSE scores with huperzine A than with placebo over 8 to 16 weeks, and an overview of six systematic reviews reached the same conclusion while calling the evidence insufficient. A phase II trial of 210 people (co-funded by Neuro-Hitech, Inc.) found no effect of 200 micrograms twice daily on its primary outcome. A Cochrane review found no eligible trials in mild cognitive impairment, and one in vascular dementia found a single trial of 14 people; a 2024 network meta-analysis of 194 trials in vascular dementia, 16 of them testing huperzine A, placed it among the top five of 21 drugs for MMSE and daily-living scores. All of this is clinical evidence, so the grade for healthy adults is capped at C.

How we grade evidence

Studies this grade rests on

EffectMixedNo effectSize shows participants (n)20052010201520202025Meta-analysisSystematic reviewRCTYang 2013, 2013: meta-analysis, n = 1,823, result not recordedDang 2024, 2024: meta-analysis, n = 1,114, result not recordedLi 2008, 2008: meta-analysis, n = 454, result not recordedRafii 2011, 2011: RCT, n = 210, result not recordedHao 2009, 2009: systematic review, n = 14, result not recordedWang 2009, 2009: meta-analysis, n not recorded, result not recordedHuang 2019, 2019: meta-analysis, n not recorded, result not recordedYue 2012, 2012: systematic review, n not recorded, result not recordedGhassab-Abdollahi 2021, 2021: systematic review, n not recorded, result not recorded
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.
Show the numbers
StudyYearDesignParticipantsResult
Li 20082008meta-analysis454result not recorded
Wang 20092009meta-analysisnot recordedresult not recorded
Hao 20092009systematic review14result not recorded
Rafii 20112011RCT210result not recorded
Yue 20122012systematic reviewnot recordedresult not recorded
Yang 20132013meta-analysis1823result not recorded
Huang 20192019meta-analysisnot recordedresult not recorded
Ghassab-Abdollahi 20212021systematic reviewnot recordedresult not recorded
Dang 20242024meta-analysis1114result not recorded

Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis.

Dang C, Wang Q, Zhuang Y. Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis Front Pharmacol, 2024. PMID 39239652

Result not recorded
Design
Systematic review and Bayesian network meta-analysis of 194 randomized trials (21 drugs vs placebo or no treatment; 16 trials of huperzine A)
Sample
n = 1,114
Population
Adults with vascular dementia (clinical population); huperzine A arm data: 572 patients, 542 controls
Funding
Public research funds: National Natural Science Foundation of China (82001240), Natural Science Foundation of Heilongjiang Province, China Postdoctoral Science Foundation, Postdoctoral Foundation of Heilongjiang Province (PMC full text)

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

Wang BS, Wang H, Wei ZH. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis J Neural Transm (Vienna), 2009. PMID 19221692

Result not recorded
Design
Meta-analysis of 4 randomized placebo-controlled trials
Population
People with Alzheimer's disease (clinical population)
Funding
Non-US Government support (PubMed publication type); funder not named in the abstract; full text not read

Huperzine A for vascular dementia.

Hao Z, Liu M, Liu Z. Huperzine A for vascular dementia Cochrane Database Syst Rev, 2009. PMID 19370686

Result not recorded
Design
Cochrane systematic review (1 trial included)
Sample
n = 14
Population
People with vascular dementia (clinical population)
Funding
not stated in the PubMed or Crossref record (declarations: none known)

[Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis].

Huang P, Li B, Guo YH. [Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis] Zhongguo Zhong Yao Za Zhi, 2019. PMID 30989926

Result not recorded
Design
Systematic review and meta-analysis of 9 randomized trials
Population
People with mild cognitive impairment (clinical population)
Funding
not stated in the PubMed or Crossref record; full text not read

Huperzine A for mild cognitive impairment.

Yue J, Dong BR, Lin X. Huperzine A for mild cognitive impairment Cochrane Database Syst Rev, 2012. PMID 23235666

Result not recorded
Design
Cochrane systematic review (no eligible trials found)
Population
People with mild cognitive impairment (clinical population)
Funding
not stated in the PubMed or Crossref record (declarations: none)

A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Rafii MS, Walsh S, Little JT. A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology, 2011. PMID 21502597

Result not recorded
Design
Phase II multicenter randomized, double-blind, placebo-controlled trial (3 arms, 16 weeks)
Sample
n = 210
Population
People with mild to moderate Alzheimer's disease (clinical population)
Funding
NIH/NIA (P30 AG008051, U19 AG010483) and Neuro-Hitech, Inc. (full text)

The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews.

Ghassab-Abdollahi N, Mobasseri K, Dehghani Ahmadabad A. The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews Phytother Res, 2021. PMID 33851462

Result not recorded
Design
Overview of 6 systematic reviews (AMSTAR quality appraisal)
Population
People with dementia or mild cognitive impairment (clinical populations)
Funding
Tabriz University of Medical Sciences

Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.

Yang G, Wang Y, Tian J. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials PLoS One, 2013. PMID 24086396

Result not recorded
Design
Systematic review and meta-analysis of 20 randomized trials (protocol CRD42012003249)
Sample
n = 1,823
Population
People with Alzheimer's disease (clinical population)
Funding
Program for Innovative Research Teams of Beijing University of Chinese Medicine; 111 Project; Chinese national herbal-medicine evaluation platform grant (full text)

Huperzine A for Alzheimer's disease.

Li J, Wu HM, Zhou RL. Huperzine A for Alzheimer's disease Cochrane Database Syst Rev, 2008. PMID 18425924

Result not recorded
Design
Cochrane systematic review and meta-analysis of 6 randomized trials
Sample
n = 454
Population
People with Alzheimer's disease (clinical population)
Funding
not stated in the PubMed or Crossref record (declarations: none known)

Search and history

Search (): huperzine[ti] AND (meta-analysis[pt] OR systematic review[pt])

  • Graded C (proposed): Proposed in the monograph draft
  • C to C (approved): Editor sign-off November 13, 2026: grade matches the editor-approved final page